Most ambitiously it is the creation of novel proteins to perform useful tasks. At a more modest level it might be identifying amino acid mutations that enhance protein stability, alter binding specificity, or increase solubility.
How do we design proteins?
We have developed a computer program that identifies low energy sequences for a target structure or interface. In essence, it is like solving a jigsaw puzzle.The pieces, in this case amino acids, must fit together so that there are no overlaps and little empty space.In addition, specific interactions such as hydrogen bonds must be satisfied.
What have we designed in the past?
In the past we have used our program to enhance protein stability, design a protein with a topology that has not been observed in nature, enhance protein-protein binding affinities and design a protein conformational switch..
What would we like to design in the future?
Currently we are focusing on a variety of design goals including the creation of protein conformational switches, the rewiring of protein signal transduction pathways, and the design of protein biosensors for live cell imaging.
Current Projects
Design of protein conformational switches. One amazing property of proteins is that they are often able to adopt multiple specific structures, each with its own functional importance. The relative stability of these states is typically regulated by ligand binding or post-translational modification. To design new proteins that switch conformation we have modified Rosetta so that it can search for a sequence that is simultaneously good for multiple target structures. We have used this algorithm do design a protein that can switch between a coiled-coil and a zinc finger. To add functionality to this switch we are now adding unique DNA binding properties to each of the two structures.
De Novo design of β -sheet proteins Despite the large number of all-β proteins in nature, the de novo design of a β -sheet protein has alluded protein designers. To create a totally novel β -protein we are using a protocol that iterates between structure refinement and sequence optimization. The challenge with β -sheet design is creating proteins that do not aggregate. We are currently focused on adding negative design elements to our sequences that prevent aggregation.
De Novo design of protein-protein interfaces.
Protein-protein interactions are essential to life. The
ability to rationally design proteins that bind to
target proteins would allow for the creation of new
therapeutics, biosensors and tools for regulating cell
biology. The de novo design of interfaces is an
extremely challenging goal because it requires creating
proteins that interact favorably with the polar amino
acids typically found on protein surfaces. To meet this
goal we are developing protocols that iterate between
sequence design, backbone refinement and rigid body
docking. We are currently investigating three methods of attack on this problem. In one method, we are trying to seed a de novo interface by grafting residues from a binding partner of a target onto a new scaffold. In another method, we are integrating metal ligand sides (for example tetrahedral Zn sites) whose sidechains are split between halves of the interface. In a third method, we are attempting to use exposed surface beta-strands as a handhold, and bind a new protein to the target via starting with the exposed strand's hydrogen bonds.
Peptide-protein interface design with non-natural amino acids. Peptide-protein interactions are of great therapeutic interest, because high-affinity peptides can modulate bioactivity when targeted toward binding sites normally occupied by other proteins or peptides. For many peptide-protein interfaces evolution has probably selected for sequences that are already close to optimal. To enhance peptide binding, therefore, it may be advantageous to consider amino acids that nature did not have at its disposal. Hydrophobic amino acids with novel geometries should help create new packing configurations while the inclusion of non-natural polar amino acids may help create more ideal hydrogen bonds. An additional feature of some non-natural amino acids is that they are more resistant to proteases, and peptides made from them may have better bioavailability.

